Drug Patents owned by Lantheus Medcl

1. Drug name - DEFINITY

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10022460 LANTHEUS MEDCL Lipid-encapsulated gas microsphere compositions and related methods
Dec, 2035

(13 years from now)

CN107206111B LANTHEUS MEDCL Lipid Encapsulated Gas Microsphere Compositions And Related Methods
Dec, 2035

(13 years from now)

CN107206111A LANTHEUS MEDCL Gas Microsphere Composition Of Lipid Encapsulation And Related Method
Dec, 2035

(13 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10583207 LANTHEUS MEDCL Lipid-encapsulated gas microsphere compositions and related methods Dec, 2035

(13 years from now)

US9789210 LANTHEUS MEDCL Methods for making ultrasound contrast agents Mar, 2037

(14 years from now)

US10583208 LANTHEUS MEDCL Methods for making ultrasound contrast agents Mar, 2037

(14 years from now)

US10588988 LANTHEUS MEDCL Methods and devices for preparation of ultrasound contrast agents May, 2037

(14 years from now)

Drugs and Companies using PERFLUTREN ingredient

Treatment: Method of using the drug substance/drug product for ultrasound imaging

Dosage: INJECTABLE;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
6.52MG/ML INJECTABLE;INTRAVENOUS Prescription

availability in other generic markets.

Click on the highlighted region to filter.